Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
76°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alterity Therapeutics Ltd ADR
(NQ:
ATHE
)
1.300
-0.020 (-1.52%)
Streaming Delayed Price
Updated: 3:13 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alterity Therapeutics Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
July 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at MST Financial Webinar
July 24, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
June 12, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
May 29, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
May 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 10, 2024
Via
Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
May 08, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 03, 2024
Via
Benzinga
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
April 30, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 23, 2024
Via
Benzinga
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 17, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
April 15, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 15, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
April 10, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
March 26, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
February 20, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 06, 2024
Via
Benzinga
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
February 06, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
January 29, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 22, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 15, 2024
Via
Benzinga
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
December 21, 2023
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
December 05, 2023
Shares of GitLab Inc. (NASDAQ: GTLB) rose sharply in pre-market trading after the company posted better-than-expected results for its third quarter and issued a stro
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 05, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.